175 related articles for article (PubMed ID: 38106570)
1. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Wong E; Nester C; Cavero T; Karras A; Le Quintrec M; Lightstone L; Eisenberger U; Soler MJ; Kavanagh D; Daina E; Praga M; Medjeral-Thomas NR; Gäckler A; Garcia-Carro C; Biondani A; Chaperon F; Kulmatycki K; Milojevic J; Webb NJA; Nidamarthy PK; Junge G; Remuzzi G
Kidney Int Rep; 2023 Dec; 8(12):2754-2764. PubMed ID: 38106570
[TBL] [Abstract][Full Text] [Related]
2. Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
Bomback AS; Kavanagh D; Vivarelli M; Meier M; Wang Y; Webb NJA; Trapani AJ; Smith RJH
Kidney Int Rep; 2022 Oct; 7(10):2150-2159. PubMed ID: 36217526
[TBL] [Abstract][Full Text] [Related]
3. Factor B Inhibition with Iptacopan in Recurrent C3 Glomerulopathy Following Kidney Transplant: A Report of Two Cases.
Escudero-Saiz VJ; Gonzalez Á; García-Herrera A; Larque AB; Bomback AS; Morantes L; Martínez-Chillarón M; Ollé J; Guillén E; Xipell M; Molina-Andújar A; Rodríguez D; Cuadrado E; Cacho J; Arana C; Esforzado N; Bastida C; Poch E; Diekman F; Cucchiari D; Quintana LF; Blasco M
Kidney Med; 2024 Jun; 6(6):100823. PubMed ID: 38741947
[TBL] [Abstract][Full Text] [Related]
4. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Zhang H; Rizk DV; Perkovic V; Maes B; Kashihara N; Rovin B; Trimarchi H; Sprangers B; Meier M; Kollins D; Papachristofi O; Milojevic J; Junge G; Nidamarthy PK; Charney A; Barratt J
Kidney Int; 2024 Jan; 105(1):189-199. PubMed ID: 37914086
[TBL] [Abstract][Full Text] [Related]
5. Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.
Vivarelli M; Bomback AS; Meier M; Wang Y; Webb NJA; Veldandi UK; Smith RJH; Kavanagh D
Kidney Int Rep; 2024 Jan; 9(1):64-72. PubMed ID: 38312795
[TBL] [Abstract][Full Text] [Related]
6. Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases.
Dixon BP; Greenbaum LA; Huang L; Rajan S; Ke C; Zhang Y; Li L
Kidney Int Rep; 2023 Nov; 8(11):2284-2293. PubMed ID: 38025230
[TBL] [Abstract][Full Text] [Related]
7. Kidney Transplantation in C3 Glomerulopathy: A Case Series.
Regunathan-Shenk R; Avasare RS; Ahn W; Canetta PA; Cohen DJ; Appel GB; Bomback AS
Am J Kidney Dis; 2019 Mar; 73(3):316-323. PubMed ID: 30413277
[TBL] [Abstract][Full Text] [Related]
8. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
9. Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy.
Kumar A; Ramachandran R; Rawat A; Das R; Rayat CS; Kenwar DB; Sharma A; Gupta KL; Nada R
Clin Kidney J; 2021 Jan; 14(1):291-300. PubMed ID: 33564431
[TBL] [Abstract][Full Text] [Related]
10. Design and Rationale of the APPELHUS Phase 3 Open-Label Study of Factor B Inhibitor Iptacopan for Atypical Hemolytic Uremic Syndrome.
Kavanagh D; Greenbaum LA; Bagga A; Karki RG; Chen CW; Vasudevan S; Charney A; Dahlke M; Fakhouri F
Kidney Int Rep; 2023 Jul; 8(7):1332-1341. PubMed ID: 37441479
[TBL] [Abstract][Full Text] [Related]
11. Defining the complement biomarker profile of C3 glomerulopathy.
Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722
[TBL] [Abstract][Full Text] [Related]
12. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.
Gonzalez Suarez ML; Thongprayoon C; Hansrivijit P; Kovvuru K; Kanduri SR; Aeddula NR; Pivovarova AI; Chewcharat A; Bathini T; Mao MA; Basu A; Cheungpasitporn W
Med Sci (Basel); 2020 Oct; 8(4):. PubMed ID: 33096866
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Rizk DV; Rovin BH; Zhang H; Kashihara N; Maes B; Trimarchi H; Perkovic V; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J
Kidney Int Rep; 2023 May; 8(5):968-979. PubMed ID: 37180505
[TBL] [Abstract][Full Text] [Related]
15. Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan.
Podos SD; Trachtman H; Appel GB; Bomback AS; Dixon BP; Wetzels JFM; Cook HT; Parikh SV; Pickering MC; Tumlin J; Langman CB; Lightstone L; Sperati CJ; Daina E; Bouman KP; Rice K; Thanassi JA; Huang M; Nester C; Remuzzi G
Am J Nephrol; 2022; 53(10):675-686. PubMed ID: 36404708
[TBL] [Abstract][Full Text] [Related]
16. C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies.
Caravaca-Fontán F; Lucientes L; Serra N; Cavero T; Rodado R; Ramos N; Gonzalez F; Shabaka A; Cabello V; Huerta A; Pampa-Saico S; Gutiérrez E; Quintana LF; López-Rubio ME; Draibe J; Alonso Titos J; Fernández-Juárez G; Goicoechea de Jorge E; Praga M
Nephrol Dial Transplant; 2022 Oct; 37(11):2128-2137. PubMed ID: 34677610
[TBL] [Abstract][Full Text] [Related]
17. Validation of a Histologic Scoring Index for C3 Glomerulopathy.
Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M;
Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150
[TBL] [Abstract][Full Text] [Related]
18. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
19. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
20. C3 glomerulopathy and current dilemmas.
Ito N; Ohashi R; Nagata M
Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
